nafamostat has been researched along with Critical Illness in 6 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat mesilate provided sufficient filter survival without causing major bleeding complications despite the prolongation of APTT." | 3.77 | Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. ( Hosoya, T; Maruyama, Y; Takinami, M; Uchino, S; Yamamoto, H; Yokoyama, K; Yoshida, H, 2011) |
| "Given the better survival outcomes, lower risk of bleeding, NM anticoagulation seems to be a safe and efficient approach for BPT patients and could yield a favorable filter lifespan." | 2.82 | Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis. ( He, J; Liao, S; Lin, Y; Liu, Y; Shao, Y; Xu, M; Yang, R; Yang, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, Y | 1 |
| Shao, Y | 1 |
| Liu, Y | 1 |
| Yang, R | 1 |
| Liao, S | 1 |
| Yang, S | 1 |
| Xu, M | 1 |
| He, J | 1 |
| Doi, K | 1 |
| Ikeda, M | 1 |
| Hayase, N | 1 |
| Moriya, K | 1 |
| Morimura, N | 1 |
| Hifumi, T | 1 |
| Isokawa, S | 1 |
| Otani, N | 1 |
| Ishimatsu, S | 1 |
| Sagawa, T | 1 |
| Inoue, KI | 1 |
| Takano, H | 1 |
| Maruyama, Y | 1 |
| Yoshida, H | 1 |
| Uchino, S | 1 |
| Yokoyama, K | 1 |
| Yamamoto, H | 1 |
| Takinami, M | 1 |
| Hosoya, T | 1 |
| Shiga, H | 1 |
| Hirasawa, H | 1 |
| Oda, S | 1 |
| Matsuda, K | 1 |
| Ueno, H | 1 |
| Nakamura, M | 1 |
1 review available for nafamostat and Critical Illness
| Article | Year |
|---|---|
Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis.
Topics: Anticoagulants; Benzamidines; COVID-19 Drug Treatment; Critical Illness; Guanidines; Heparin; Hepari | 2022 |
5 other studies available for nafamostat and Critical Illness
| Article | Year |
|---|---|
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.
Topics: Aged; Amides; Benzamidines; Coronavirus Infections; COVID-19 Drug Treatment; Critical Illness; Drug | 2020 |
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidine | 2020 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illne | 2020 |
Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Benzamidines; Cr | 2011 |
Continuous hemodiafiltration in pediatric critical care patients.
Topics: Adolescent; Anticoagulants; Benzamidines; Body Size; Body Temperature; Child; Child, Preschool; Crit | 2004 |